Aberrant basement membrane production by HSCs in MASLD is attenuated by the bile acid analog INT-767

The farnesoid X receptor (FXR) is a leading therapeutic target for metabolic dysfunction-associated steatohepatitis (MASH)-related fibrosis. INT-767, a potent FXR agonist, has shown promise in preclinical models. We aimed to define the mechanisms of INT-767 activity in experimental MASH and dissect...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Hepatology communications 2024-12, Vol.8 (12)
Hauptverfasser:	Ramachandran, Prakash, Brice, Madara, Sutherland, Elena F, Hoy, Anna M, Papachristoforou, Eleni, Jia, Li, Turner, Frances, Kendall, Timothy J, Marwick, John A, Carragher, Neil O, Oro, Denise, Feigh, Michael, Leeming, Diana J, Nielsen, Mette J, Karsdal, Morten A, Hartmann, Nadine, Erickson, Mary, Adorini, Luciano, Roth, Jonathan D, Fallowfield, Jonathan A
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Basement Membrane - drug effects Basement Membrane - metabolism Basement Membrane - pathology Bile Acids and Salts - metabolism Cholic Acids - pharmacology Disease Models, Animal Fatty Liver - drug therapy Fatty Liver - metabolism Fatty Liver - pathology Hepatic Stellate Cells - drug effects Hepatic Stellate Cells - metabolism Humans Liver - drug effects Liver - metabolism Liver - pathology Liver Cirrhosis - drug therapy Liver Cirrhosis - metabolism Liver Cirrhosis - pathology Male Mice Original Receptors, Cytoplasmic and Nuclear - agonists Receptors, Cytoplasmic and Nuclear - genetics Receptors, Cytoplasmic and Nuclear - metabolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!